p300 interacts with the N- and C-terminal part of PPARgamma2 in a ligand-independent and -dependent manner, respectively
about
Synergy between estrogen receptor alpha activation functions AF1 and AF2 mediated by transcription intermediary factor TIF2.Transcription factors and nuclear receptors interact with the SWI/SNF complex through the BAF60c subunitSDP1 is a peroxisome-proliferator-activated receptor gamma 2 co-activator that binds through its SCAN domainIdentification and characterization of ART-27, a novel coactivator for the androgen receptor N terminusPPARgamma1 and LXRalpha face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1Convergence of two repressors through heterodimer formation of androgen receptor and testicular orphan receptor-4: a unique signaling pathway in the steroid receptor superfamilyInsulin-like growth factors and their potential role in cardiac epigeneticsModulation of the transcriptional activity of peroxisome proliferator-activated receptor gamma by protein-protein interactions and post-translational modificationsRole of Nuclear Receptors in Central Nervous System Development and Associated DiseasesFate determination in mesenchymal stem cells: a perspective from histone-modifying enzymesPPARγ as a therapeutic target to rescue mitochondrial function in neurological diseaseCyclin D1 represses p300 transactivation through a cyclin-dependent kinase-independent mechanismCorepressors selectively control the transcriptional activity of PPARgamma in adipocytesLiver Patt1 deficiency protects male mice from age-associated but not high-fat diet-induced hepatic steatosisCharacterization of the amino-terminal activation domain of peroxisome proliferator-activated receptor alpha. Importance of alpha-helical structure in the transactivating function.Core LXXLL motif sequences in CREB-binding protein, SRC1, and RIP140 define affinity and selectivity for steroid and retinoid receptors.Anti-diabetic rosiglitazone remodels the adipocyte transcriptome by redistributing transcription to PPARγ-driven enhancers.Peroxisome proliferator-activated receptor-gamma: a versatile metabolic regulator.Proteasomal degradation of retinoid X receptor alpha reprograms transcriptional activity of PPARgamma in obese mice and humansMED14 tethers mediator to the N-terminal domain of peroxisome proliferator-activated receptor gamma and is required for full transcriptional activity and adipogenesis.Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene.Inhibition of cellular proliferation through IkappaB kinase-independent and peroxisome proliferator-activated receptor gamma-dependent repression of cyclin D1.The LIM protein Ajuba promotes adipogenesis by enhancing PPARγ and p300/CBP interactionInsulin sensitiser drugs.Coactivators in PPAR-Regulated Gene ExpressionCyclin D3 promotes adipogenesis through activation of peroxisome proliferator-activated receptor gamma.Homeostatic levels of SRC-2 and SRC-3 promote early human adipogenesis.The endocrine disruptor monoethyl-hexyl-phthalate is a selective peroxisome proliferator-activated receptor gamma modulator that promotes adipogenesis.ARTD1-induced poly-ADP-ribose formation enhances PPARγ ligand binding and co-factor exchangeHistone deacetylase inhibitors stimulate mitochondrial HMG-CoA synthase gene expression via a promoter proximal Sp1 site.PPAR and immune system--what do we know?Arginine decreases peroxisome proliferator-activated receptor-γ activity via c-Jun.G Protein-coupled Receptor 40 (GPR40) and Peroxisome Proliferator-activated Receptor γ (PPARγ): AN INTEGRATED TWO-RECEPTOR SIGNALING PATHWAY.Transcriptional control of adipocyte formation.Histone H3 K27 acetylation marks a potent enhancer element on the adipogenic master regulator gene Pparg2.Inhibiting adipose tissue lipogenesis reprograms thermogenesis and PPARγ activation to decrease diet-induced obesityDynamic and distinct histone modifications modulate the expression of key adipogenesis regulatory genes.Mechanisms Mediating the Effects of γ-Tocotrienol When Used in Combination with PPARγ Agonists or Antagonists on MCF-7 and MDA-MB-231 Breast Cancer CellsNuclear Receptor Cofactors in PPARgamma-Mediated Adipogenesis and Adipocyte Energy Metabolism.Chromatin and chromatin-modifying proteins in adipogenesis.
P2860
Q24290966-6A3674B4-A6EC-4320-80AE-F90B1125AE04Q24303852-BD38B72D-A60D-49F7-9874-3BAC33121D98Q24535573-E4F58182-7C00-4FAE-B744-43D77FA49F38Q24555034-1DA7C9FC-BCC2-4E2D-89F7-A2728D1827E4Q24633440-A091D244-BA9A-4789-881C-35E4864F5178Q24657742-88AF924B-FA53-4A0A-BA74-6B3C86F0E43BQ26750525-43B0203C-E989-402E-9D21-8679E66763F3Q27015807-219429D1-0690-465A-A9C4-294871BDD9E0Q27025212-72183D03-DF33-44B2-9791-4F2A4C90CC2EQ27692571-4591312D-C407-48D9-A296-6EF74379C147Q28069549-C582A709-27F3-410C-91EF-A212992C1721Q28256059-0CE9E163-D6DC-42A0-AE78-A963CFC08C7BQ28508812-0D9BFA72-2348-4B08-A90A-DE4D7DEC4D05Q28586093-5DF5C77C-7E00-4867-B75B-9A3EC3C2D633Q30323774-0C62FC4F-7C85-42D8-8B60-7E37353C46B6Q31568030-56999B7B-03D9-450E-A91A-9E99A55118E5Q33600223-01F0E06E-08DC-4C64-B1D4-64C35ACC19B6Q33780711-C74C6E75-AC3E-4238-B724-F5888AC2D830Q33815655-7EBC68ED-2D19-4206-9772-6B8FF90A721EQ33826208-B6937DB0-2F1B-4004-855B-122E530F64F5Q33964333-C0E95974-9DE1-46C7-AED7-DCC0D3C03F7CQ33967999-0C9A1D86-64EF-4305-84BA-18CFA6670EF3Q34044339-C7B07FFF-FA2B-473F-A3B0-545F014E238BQ34074912-5D0A03E3-62BB-483C-8F35-B719338C08AEQ34089711-8B329161-3562-47C3-9FC0-6EAD6D2DCE6CQ34124151-A8EF6540-26AC-482D-A27A-D005057862DDQ34483124-00071D76-BA16-4530-9632-B525F702315CQ34623928-371B56FA-1406-43AE-BF70-B16E5B6F3EE1Q34883050-222FE754-3ACF-48A0-9C87-9B6FD0A2F524Q34909281-EB2FDD66-B5F7-49EE-A8DE-AC3B1A653E73Q34913467-997EC8D8-0891-4366-B537-101246BD1670Q35722757-4BAFF93A-CE83-41B8-880C-2976912E1418Q35925797-39828CB6-9734-4734-8715-25C25618BEC1Q35962266-6BC5905B-3390-47B6-B4D0-3FEEDA1F4C05Q36188264-039F4687-19DD-4310-8801-495F80BAFA78Q36306320-9F0AFE99-87EE-45CC-BEEB-E11472105982Q36556295-4BBB648C-5B94-451A-A8A7-C5F13C7724F8Q36602967-CE452A60-5B24-459B-8087-D211DFF66136Q36772290-450BAE7D-E920-4802-9BA0-DC0B6928B167Q36916637-BCBBCC35-4994-48C0-94B9-3B37548C56AB
P2860
p300 interacts with the N- and C-terminal part of PPARgamma2 in a ligand-independent and -dependent manner, respectively
description
1999 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մարտին հրատարակված գիտական հոդված
@hy
article publié dans la revue scientifique Journal of Biological Chemistry
@fr
artículu científicu espublizáu en 1999
@ast
im März 1999 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 1999/03/19)
@sk
vědecký článek publikovaný v roce 1999
@cs
wetenschappelijk artikel (gepubliceerd op 1999/03/19)
@nl
наукова стаття, опублікована в березні 1999
@uk
name
p300 interacts with the N- and ...... dependent manner, respectively
@ast
p300 interacts with the N- and ...... dependent manner, respectively
@en
p300 interacts with the N- and ...... dependent manner, respectively
@nl
type
label
p300 interacts with the N- and ...... dependent manner, respectively
@ast
p300 interacts with the N- and ...... dependent manner, respectively
@en
p300 interacts with the N- and ...... dependent manner, respectively
@nl
prefLabel
p300 interacts with the N- and ...... dependent manner, respectively
@ast
p300 interacts with the N- and ...... dependent manner, respectively
@en
p300 interacts with the N- and ...... dependent manner, respectively
@nl
P2093
P2860
P3181
P356
P1476
p300 interacts with the N- and ...... dependent manner, respectively
@en
P2093
P2860
P304
P3181
P356
10.1074/JBC.274.12.7681
P407
P50
P577
1999-03-19T00:00:00Z